Joe Dennis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Joe Dennis has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Douglas F. Easton
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge , Cambridge CB1 8RN
74 shared publications - Kyriaki Michailidou
Department of Biostatistics, the Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
64 shared publications - Heli Nevanlinna
Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
63 shared publications Georgia Chenevix-Trench
Cancer Research Program, QIMR Berghofer, Brisbane, Australia
60 shared publicationsDouglas F. Easton
Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge, UK
57 shared publications- Paul David Peter Pharoah
Department of Computational Biomedicine, Cedars-Sinai Medical Center, West Hollywood, CA, USA
57 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Communications Medicine
Fine-mapping of breast cancer susceptibility loci highlights critical methodological dependencies and the value of complementary approaches
- 2 November 2026
- Published by Springer Nature in Communications Medicine
Open AccessFine-mapping of breast cancer susceptibility loci highlights critical methodological dependencies and the value of complementary approaches
- 28 September 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (6)
Genetic and cellular architecture of breast cancer risk across ancestries
Background: Breast cancer genome-wide association studies (GWAS) have identified more than 200 susceptibility loci, but most studies are dominated by European and East Asian populations. Methods: We analyzed breast cancer GWAS summary statistics from African (AFR), East Asian (EAS), European (EUR), and Hispanic/Latina (H/L) samples (159 297 cases and 212 102 controls). We estimated logit-scale SNP-based heritability, polygenicity, and cross-ancestry genetic correlation, partitioned heritability across functional annotations, and integrated GWAS results with the Tabula Sapiens single-cell atlas using scDRS+. Results: The logit-scale heritability of breast cancer ranged from h2 = 0.47 (SE = 0.07) in EAS to AFR h2 = 0.61 (SE = 0.10), with no significant differences across ancestries (P = .63). The model-implied number of non-null susceptibility SNPs in the sparse normal-mixture effect-size model also varied from 4446 (SE = 3100) in EAS to 8308 (SE = 2751) in AFR, but differences were not significant across ancestries (P = .55). Cross-sample genetic correlations varied, with the strongest correlation between EUR and EAS (ρ=0.79, SE = 0.08) and weakest between AFR and H/L (ρ=0.26, SE = 0.24). Regulatory annotations were enriched for breast cancer heritability across samples. Integration with single-cell expression profiles implicated ancestry-shared associations with innate immune, secretory epithelial, and stromal cell types. Conclusion: These results indicate substantial cross-ancestry sharing of breast cancer polygenic architecture, highlight a consistent contribution of regulatory variation, and identify convergent cellular contexts that motivate functional follow-up and inform expectations for the transferability and attainable performance of common-variant risk prediction across populations.
- 28 September 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (6)
Genetic and cellular architecture of breast cancer risk across ancestries
Background: Breast cancer genome-wide association studies (GWAS) have identified more than 200 susceptibility loci, but most studies are dominated by European and East Asian populations. Methods: We analyzed breast cancer GWAS summary statistics from African (AFR), East Asian (EAS), European (EUR), and Hispanic/Latina (H/L) samples (159 297 cases and 212 102 controls). We estimated logit-scale SNP-based heritability, polygenicity, and cross-ancestry genetic correlation, partitioned heritability across functional annotations, and integrated GWAS results with the Tabula Sapiens single-cell atlas using scDRS+. Results: The logit-scale heritability of breast cancer ranged from h2 = 0.47 (SE = 0.07) in EAS to AFR h2 = 0.61 (SE = 0.10), with no significant differences across ancestries (P = .63). The model-implied number of non-null susceptibility SNPs in the sparse normal-mixture effect-size model also varied from 4446 (SE = 3100) in EAS to 8308 (SE = 2751) in AFR, but differences were not significant across ancestries (P = .55). Cross-sample genetic correlations varied, with the strongest correlation between EUR and EAS (ρ=0.79, SE = 0.08) and weakest between AFR and H/L (ρ=0.26, SE = 0.24). Regulatory annotations were enriched for breast cancer heritability across samples. Integration with single-cell expression profiles implicated ancestry-shared associations with innate immune, secretory epithelial, and stromal cell types. Conclusion: These results indicate substantial cross-ancestry sharing of breast cancer polygenic architecture, highlight a consistent contribution of regulatory variation, and identify convergent cellular contexts that motivate functional follow-up and inform expectations for the transferability and attainable performance of common-variant risk prediction across populations.
- Open Access
- 27 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 60
A genome-wide association study on radiation induced fibrosis in breast cancer patients
- 27 April 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 60
Open AccessA genome-wide association study on radiation induced fibrosis in breast cancer patients
- Open Access
Comparative fine-mapping of breast cancer susceptibility loci using summary statistics methods and multinomial regression
Summary statistics fine-mapping methods offer advantages over classical methods, including avoiding data-sharing constraints and improved modelling of correlated variables and sparse effects. However, its performance has not been comprehensively evaluated in breast cancer using real-world data. Previous multinomial stepwise regression (MNR) fine-mapping analyses for breast cancer identified 196 credible sets. Here, we apply summary statistics fine-mapping, compare methods, and assess parameters influencing performance. Using summary statistics from the Breast Cancer Association Consortium, we compared finiMOM, SuSiE , and FINEMAP to published MNR results across 129 regions. Performance was assessed by recall using in-sample and out-of-sample LD. Discordant credible sets were examined for technical factors, and target genes were defined using the INQUISIT pipeline. SuSiE showed the closest agreement with MNR. Results varied across regions depending on the assumed number of causal variants ( L ), with higher values reducing recall and no single L maximising performance. At optimal L per region, SuSiE identified 8,192 CCVs in 244 credible sets, with recall of 88%, 86%, and 72% for overall, ER-positive, and ER-negative breast cancer. Thirty MNR sets were missed. Discordance was partially explained by allele flips, imputation quality, and array heterogeneity. Fifty-two MNR-identified genes, including BRCA2, WNT7B and CREBBP were not recovered, while additional candidate genes were identified. Using out-of-sample LD reduced recall by 3% but identified novel variants. Fine-mapping results vary across methods, and no single approach is sufficient. The choice of L strongly influences results, and combining analytical approaches with functional validation can improve causal variant identification.
Open AccessComparative fine-mapping of breast cancer susceptibility loci using summary statistics methods and multinomial regression
Summary statistics fine-mapping methods offer advantages over classical methods, including avoiding data-sharing constraints and improved modelling of correlated variables and sparse effects. However, its performance has not been comprehensively evaluated in breast cancer using real-world data. Previous multinomial stepwise regression (MNR) fine-mapping analyses for breast cancer identified 196 credible sets. Here, we apply summary statistics fine-mapping, compare methods, and assess parameters influencing performance. Using summary statistics from the Breast Cancer Association Consortium, we compared finiMOM, SuSiE , and FINEMAP to published MNR results across 129 regions. Performance was assessed by recall using in-sample and out-of-sample LD. Discordant credible sets were examined for technical factors, and target genes were defined using the INQUISIT pipeline. SuSiE showed the closest agreement with MNR. Results varied across regions depending on the assumed number of causal variants ( L ), with higher values reducing recall and no single L maximising performance. At optimal L per region, SuSiE identified 8,192 CCVs in 244 credible sets, with recall of 88%, 86%, and 72% for overall, ER-positive, and ER-negative breast cancer. Thirty MNR sets were missed. Discordance was partially explained by allele flips, imputation quality, and array heterogeneity. Fifty-two MNR-identified genes, including BRCA2, WNT7B and CREBBP were not recovered, while additional candidate genes were identified. Using out-of-sample LD reduced recall by 3% but identified novel variants. Fine-mapping results vary across methods, and no single approach is sufficient. The choice of L strongly influences results, and combining analytical approaches with functional validation can improve causal variant identification.
- Open Access
- 30 March 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (10) , 1479-1487
Natural menopause, menarche and breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: a Mendelian randomization analysis
Background: The influence of age at menarche (AAM) and age at natural menopause (ANM) on breast cancer (BC) risk in BRCA1 and BRCA2 germline pathogenic variant (PV) carriers is uncertain. Observational studies are prone to bias and have limited statistical power. Mendelian randomization (MR) minimises bias and may be used to examine causal effects. Methods: Two-sample and age-specific MR analyses for BC were performed. For AAM, two-sample multivariable MR and mediation analyses to account for the confounding effect of body mass index (BMI), were undertaken. Results: Genetic scores for ANM and AAM predicted the respective traits in PV carriers. Inverse-variance weighted hazard ratios (HR) for genetically predicted ANM per-year were HR = 0.99 (95%CI:0.97–1.01, p = 0.45) and HR = 1.04 (95% CI:1.01–1.06, p = 0.003) for BRCA1 and BRCA2 PV carriers, respectively. After adjusting for genetic associations with BMI, AAM per-year on BC risk were HR = 0.90 (95%CI:0.83–0.98, p = 0.01) and HR = 0.95 (95%CI:0.86–1.04, p = 0.26) for BRCA1 and BRCA2 carriers, respectively, consistent with a protective effect of later AAM. Discussion: MR analyses support causal associations between ANM and BC risk in BRCA2 , but not BRCA1 , and between AAM and BC risk in BRCA1 and BRCA2 PV carriers. These results may aid risk prediction models and genetic counselling of carriers.
- 30 March 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (10) , 1479-1487
Open AccessNatural menopause, menarche and breast cancer risk in BRCA1 and BRCA2 pathogenic variant carriers: a Mendelian randomization analysis
Background: The influence of age at menarche (AAM) and age at natural menopause (ANM) on breast cancer (BC) risk in BRCA1 and BRCA2 germline pathogenic variant (PV) carriers is uncertain. Observational studies are prone to bias and have limited statistical power. Mendelian randomization (MR) minimises bias and may be used to examine causal effects. Methods: Two-sample and age-specific MR analyses for BC were performed. For AAM, two-sample multivariable MR and mediation analyses to account for the confounding effect of body mass index (BMI), were undertaken. Results: Genetic scores for ANM and AAM predicted the respective traits in PV carriers. Inverse-variance weighted hazard ratios (HR) for genetically predicted ANM per-year were HR = 0.99 (95%CI:0.97–1.01, p = 0.45) and HR = 1.04 (95% CI:1.01–1.06, p = 0.003) for BRCA1 and BRCA2 PV carriers, respectively. After adjusting for genetic associations with BMI, AAM per-year on BC risk were HR = 0.90 (95%CI:0.83–0.98, p = 0.01) and HR = 0.95 (95%CI:0.86–1.04, p = 0.26) for BRCA1 and BRCA2 carriers, respectively, consistent with a protective effect of later AAM. Discussion: MR analyses support causal associations between ANM and BC risk in BRCA2 , but not BRCA1 , and between AAM and BC risk in BRCA1 and BRCA2 PV carriers. These results may aid risk prediction models and genetic counselling of carriers.
- Open Access
- 23 March 2026
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 35 (6)
A reanalysis of a genome-wide association study on breast cancer in Asian populations using the SG10K_Health reference panel for imputation: a multi-Centre case–control analysis
Genome-wide association studies (GWAS) have identified numerous genetic variants linked to breast cancer risk, but most discoveries come from European populations, limiting their applicability to other populations. Here, we show that the choice of genotype imputation reference panel, an essential step for GWAS, affects variant detection in Asian populations. Using two large breast cancer datasets from the Breast Cancer Association Consortium (n = 38 954 Asian samples), we compared the 1000 Genomes (1KG) reference panel with SG10K_Health (SG10K), an Asian-specific panel. SG10K imputed more rare variants and achieved higher accuracy for rare alleles (MAF < 0.001), while 1KG performed better for common variants in some contexts. Differences in panel performance influenced association signals, including breast cancer candidate loci such as FGFR2, TOX3, and ESR1. Together, these findings support the use of population-specific imputation panels as a means to improve variant discovery in underrepresented populations.
- 23 March 2026
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 35 (6)
Open AccessA reanalysis of a genome-wide association study on breast cancer in Asian populations using the SG10K_Health reference panel for imputation: a multi-Centre case–control analysis
Genome-wide association studies (GWAS) have identified numerous genetic variants linked to breast cancer risk, but most discoveries come from European populations, limiting their applicability to other populations. Here, we show that the choice of genotype imputation reference panel, an essential step for GWAS, affects variant detection in Asian populations. Using two large breast cancer datasets from the Breast Cancer Association Consortium (n = 38 954 Asian samples), we compared the 1000 Genomes (1KG) reference panel with SG10K_Health (SG10K), an Asian-specific panel. SG10K imputed more rare variants and achieved higher accuracy for rare alleles (MAF < 0.001), while 1KG performed better for common variants in some contexts. Differences in panel performance influenced association signals, including breast cancer candidate loci such as FGFR2, TOX3, and ESR1. Together, these findings support the use of population-specific imputation panels as a means to improve variant discovery in underrepresented populations.
- Open Access
- 19 March 2026
- Published by Elsevier in SSRN Electronic Journal
A Genome-Wide Association Study on Radiation Induced Fibrosis in Breast Cancer Patients
Background and purposeRadiation-induced fibrosis affects women having undergone post-lumpectomy radiotherapy to a varying degree. Publications have identified Single Nucleotide Polymorphisms (SNPs) associated with fibrosis after radiotherapy in breast cancer patients. We aimed to identify new genetic variants in a cohort of early breast cancer patients representing two cohorts treated within the Danish Breast Cancer Group (DBCG) protocols.Patients/material and methodsThe genome-wide-association-analysis included 869 patients treated with lumpectomy and adjuvant radiotherapy in the DBCG trials hypo- versus normofractionated radiotherapy trial, DBCG-HYPO, and the DBCG partial versus whole breast irradiation trial, DBCG-PBI.Samples were genotyped using the Illumina Infinium OncoArray Bead Chip. Associations between common genetic variants and fibrosis grade 2 or 3 (LENT-SOMA) in a per-risk allele log-additive genetic model were tested in an exploratory genome-wide association study (GWAS). A genome-wide significance cut-off of P < 5x10-8 was applied.ResultsAn association reaching a P-value = 5.90 x10-8 after removal of principal component outliers was identified in a locus on chromosome 10. The strongest association was represented by the SNP rs75542274.InterpretationAn exploratory GWAS identified a locus on chromosome 10 reaching a near-significant genome-wide association with radiation-induced fibrosis. This finding must be tested in – or meta-analysed with - independent studies.
- 19 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessA Genome-Wide Association Study on Radiation Induced Fibrosis in Breast Cancer Patients
Background and purposeRadiation-induced fibrosis affects women having undergone post-lumpectomy radiotherapy to a varying degree. Publications have identified Single Nucleotide Polymorphisms (SNPs) associated with fibrosis after radiotherapy in breast cancer patients. We aimed to identify new genetic variants in a cohort of early breast cancer patients representing two cohorts treated within the Danish Breast Cancer Group (DBCG) protocols.Patients/material and methodsThe genome-wide-association-analysis included 869 patients treated with lumpectomy and adjuvant radiotherapy in the DBCG trials hypo- versus normofractionated radiotherapy trial, DBCG-HYPO, and the DBCG partial versus whole breast irradiation trial, DBCG-PBI.Samples were genotyped using the Illumina Infinium OncoArray Bead Chip. Associations between common genetic variants and fibrosis grade 2 or 3 (LENT-SOMA) in a per-risk allele log-additive genetic model were tested in an exploratory genome-wide association study (GWAS). A genome-wide significance cut-off of P < 5x10-8 was applied.ResultsAn association reaching a P-value = 5.90 x10-8 after removal of principal component outliers was identified in a locus on chromosome 10. The strongest association was represented by the SNP rs75542274.InterpretationAn exploratory GWAS identified a locus on chromosome 10 reaching a near-significant genome-wide association with radiation-induced fibrosis. This finding must be tested in – or meta-analysed with - independent studies.
- Open Access
- 8 January 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (6) , 939-948
The current state of polygenic scores for the development of lung cancer: a systematic review and validation in UK Biobank
Background: Risk-stratified lung cancer screening programs identify high-risk individuals who use tobacco but do not account for underlying genetic susceptibility. Many polygenic scores (PGS) have been developed for lung cancer, but it is unclear which, if any, are suitable for identifying high-risk individuals in the general population. Methods: We used a systematic review to identify published lung cancer PGS, which were implemented and validated in the UK Biobank (UKB) cohort. Performance (discrimination and accuracy) was compared. Subgroup analyses by sex, ethnicity, and smoking status identified differences across the population. Results: We identified 60 lung cancer PGS published since 2012. Most scores were associated with lung cancer risk in UKB. Of the 39 evaluated PGS, 33 had a hazard ratio per standard deviation greater than 1.1 and 22 had a C-index greater than 0.55. Most PGS perform better in individuals who use tobacco than those who do not, although for a small number of scores ( n = 8) the reverse is true. Discussion: Performance of lung cancer PGS is weak compared to scores for other cancers; the potential benefit of combining genetics with other risk factors for lung cancer remains unclear. Selection of a suitable score is context dependent and requires consideration of the characteristics of the target population (such as ethnicity and tobacco usage).
- 8 January 2026
- Published by Springer Nature in British Journal of Cancer
- Vol. 134 (6) , 939-948
Open AccessThe current state of polygenic scores for the development of lung cancer: a systematic review and validation in UK Biobank
Background: Risk-stratified lung cancer screening programs identify high-risk individuals who use tobacco but do not account for underlying genetic susceptibility. Many polygenic scores (PGS) have been developed for lung cancer, but it is unclear which, if any, are suitable for identifying high-risk individuals in the general population. Methods: We used a systematic review to identify published lung cancer PGS, which were implemented and validated in the UK Biobank (UKB) cohort. Performance (discrimination and accuracy) was compared. Subgroup analyses by sex, ethnicity, and smoking status identified differences across the population. Results: We identified 60 lung cancer PGS published since 2012. Most scores were associated with lung cancer risk in UKB. Of the 39 evaluated PGS, 33 had a hazard ratio per standard deviation greater than 1.1 and 22 had a C-index greater than 0.55. Most PGS perform better in individuals who use tobacco than those who do not, although for a small number of scores ( n = 8) the reverse is true. Discussion: Performance of lung cancer PGS is weak compared to scores for other cancers; the potential benefit of combining genetics with other risk factors for lung cancer remains unclear. Selection of a suitable score is context dependent and requires consideration of the characteristics of the target population (such as ethnicity and tobacco usage).
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Table S3 shows SNPs and weights for the BCAC PRS313.
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Table S3 shows SNPs and weights for the BCAC PRS313.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Methods provides details of methodology
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model
Supplementary Methods provides details of methodology